Relapsing Multiple Sclerosis (RMS)

Also known as: Relapsed Multiple sclerosis / Multiple Sclerosis Relapse / Relapsing Multiple Sclerosis / Multiple sclerosis flare

DrugDrug NameDrug Description
DB00111DaclizumabHumanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody.
DB11988OcrelizumabOcrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis. It is injection, for intravenous use. Initial U.S. Approval: 2017
DrugDrug NamePhaseStatusCount
DB05092CDP3231 / 2Completed1
DB00108Natalizumab2Terminated1
DB06650Ofatumumab2Not Yet Recruiting1
DB12612Ozanimod2 / 3Completed1
DB08868Fingolimod3Completed2
DB00060Interferon beta-1a3Active Not Recruiting2
DB00068Interferon beta-1b3Terminated1
DB06685Laquinimod3Terminated2
DB00788Naproxen3Completed1
DB11988Ocrelizumab3Active Not Recruiting2
DB11988Ocrelizumab3Recruiting1
DB06650Ofatumumab3Recruiting1
DB12612Ozanimod3Completed1
DB09122Peginterferon beta-1a3Completed3
DB12016Ponesimod3Active Not Recruiting1
DB08880Teriflunomide3Active Not Recruiting1
DB08880Teriflunomide3Recruiting3
DB08880Teriflunomide3Terminated1
DB11850Ublituximab3Recruiting2
DB08868Fingolimod4Recruiting1
DB00060Interferon beta-1a4Completed1
DB00108Natalizumab4Terminated1
DB09122Peginterferon beta-1a4Withdrawn1
DB00060Interferon beta-1aNot AvailableCompleted1
DB00060Interferon beta-1aNot AvailableRecruiting1
DB00108NatalizumabNot AvailableCompleted1
DB09153Sodium ChlorideNot AvailableCompleted1